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Law, Ethics, Religion, and Clinical Translation in the
21st Century—A Discussion with Derek Hei
About Dr. Hei
Dr. Hei received his B.S. in Chemical Engineering in 1988
from the University of Wisconsin at Madison and went on to
complete his Ph.D. in Biochemical Engineering at the Univer-
sity of California at Berkeley in 1993. He then entered indus-
try, where he worked for seven years at Genentech and then
Cerus Corp., developing recombinant protein and cell-based
biotherapeutics and rising to the position of Director of Bio-
medical Engineering at Cerus Corp. In 2000, he joined the
Waisman Center at UW–Madison to lead development of the
Waisman Clinical Biomanufacturing Facility (WCBF), a non-
proﬁt technology development and clinical manufacturing
support core that works with academic investigators and bio-
technology companies. The WCBF recently received 8.8 mil-
lion dollars in funding from the National Heart, Lung, and
Blood Institute for their Production Assistance for Cell Thera-
peutics (PACT) program. Now Technical Director and Senior
Scientist at WCBF, Dr. Hei leads a team of scientists and
engineers that support academic researchers and start-up bio-
technology companies that are involved in developing biother-
apeutics for early-stage human clinical trials. The WCBF has
advanced a variety of biotherapeutics into human clinical tri-
als including recombinant proteins, plasmid DNA, viral vec-
tors, and cell therapeutics. Dr. Hei has also been a Principal
Investigator on the National Stem Cell Bank project. In addi-
tion to his numerous peer-reviewed publications, Dr. Hei also
currently holds nine patents.
The National Stem Cell Bank and the Wisconsin
International Stem Cell Bank
In September 2005, the National Stem Cell Bank (NSCB)
was established in Madison, Wisconsin, as an NIH-funded
resource to grow, characterize, and distribute cell lines listed
on the NIH Human Pluripotent Stem Cell Registry (a list of
embryonic stem cells lines eligible for use in federally funded
research), and to provide comprehensive technical support to
stem cell researchers around the world.
The NSCB with Derek Hei and James Thomson as Direc-
tors has been hosted by the WiCell Research Institute, a non-
proﬁt, supporting organization of the University of Wisconsin
at Madison established in 1999 to focus on enhancing and
expanding the study of human pluripotent stem cells by sup-
porting basic research, establishing research protocols, and
creating and distributing cell lines. They also provide training
to scientists worldwide, and supporting efforts to unlock the
therapeutic potential of stem cell technologies.
As Dr. Hei explains ‘‘The NSCB distributes human ES
cell lines, including genetically engineered cell lines (e.g., re-
porter cell lines), for research applications. These cell lines
are obtained through voluntary donations. The NSCB regu-
lates the use of cells only through the Material Transfer
Agreement. In signing this MTA, investigators agree that they
will not perform speciﬁc types of experiments. The NSCB
also requests that the investigators have their research
approved by local Stem Cell Research Oversight (SCRO)
committees at the researcher’s institution.
Unfortunately, the NSCB’s funding will end on February
28, 2010, and the NIH currently has not discussed any plans
for continued funding. The Wisconsin International Stem Cell
Bank (WISC) will likely continue to distribute hESC lines.’’
The WISC bank (http://www.wicell.org) was originally estab-
lished by WiCell in 1999 to cover distribution of hES cells as
well as other pluripotent stem cell lines not included in the
National Stem Cell Bank. The NSCB and WiCell have
shipped cells to more than 800 researchers in 32 countries
and 42 states. WiCell also runs an exceptional education and
outreach program that provides training for scientists and
offers educational programs for K-12 students and the general
community.
‘‘I Think That It’s Important to Find Ways to
Standardize Cell Characterization Methods and
Establish Biomarkers of Clinical Outcomes’’
The WCBF is a state-of-the-art cleanroom facility (not GMP)
designed to manufacture cell and gene therapeutics for early-
stage (Phase I and Phase II) human clinical trials according to
the FDA’s cGMP guidelines for early-stage human clinical
trials. As Technical Director and Senior Scientist at WCBF,
Dr. Hei interacts with academic investigators and companies
to address technical issues related to the development and
production of cutting-edge biotherapeutics and the standardi-
zation of results.
‘‘For mesenchymal stem cells in particular, it seems that
there are many clinical trials being conducted with varying
clinical outcomes. I think that it’s important to ﬁnd ways to
standardize cell characterization methods and establish bio-
markers of clinical outcomes. This is obviously not an easy
task given that we don’t always clearly understand what prop-
erties are key to clinical outcomes. The development of better
in vitro and in vivo potency assays could help in this regard.
Genetic stability is another big issue. We need to know what
key factors impact genetic stability as well as the impact of
low levels of abnormal cells on the safety proﬁle for stem
cell-based therapeutics. We need to ask questions, such as
whether genetic stability differs from line to line, and deter-
mine the critical steps in culture and cryopreservation that
contribute to the development of abnormal karyotypes. I think
that we also need a better understanding of the impact of
Correspondence: Majlinda Lako, Institute of Human Genetics and NESCI, Newcastle University, International Centre for Life, Central
Parkway, Newcastle NE1 3BZ, United Kingdom, Received February 5, 2010; accepted for publication February 5, 2010 ﬁrst published
online in STEM CELLS EXPRESS February 17, 2010. V C AlphaMed Press 1066-5099/2010/$30.00/0 doi: 10.1002/stem.323
STEM CELLS 2010;28:387–389 www.StemCells.comresidual undifferentiated ES cells, along with methods for
detecting and removing those cells, and animal models for
determining the impact of speciﬁc levels of undifferentiated
cells on product safety. Geron has worked through some of
these issues in preparing their data package for their Investi-
gative New Drug (IND) ﬁling. However, this information is
conﬁdential and is not shared with the public sector. It would
be useful to have work done in this area that can be shared
with other translational investigators to help investigators
move through these issues to IND ﬁlings more efﬁciently.’’
‘‘I Think That Clinical Development Will Be the
Most Important Aspect of Stem Cell Research over
the Next 10–15 Years’’
‘‘One of the most important aspects of stem cell research to
be followed over the next 10 years will certainly be the devel-
opment of technologies for creating iPS (induced pluripotent
stem) cells. The ability to create disease models for studying
developmental issues and screening potential therapeutics
could be a huge near-term pay-off. The therapeutic side of
iPS cells is obviously much cloudier even with the develop-
ment of non-integrating reprogramming vectors. The effect of
reprogramming on cell epigenetics, involvement of oncogenes
in the reprogramming process, and process efﬁciency and
reproducibility from patient to patient are some of the many
key issues that need to be resolved before iPS cell-based clin-
ical applications can become a reality.’’
‘‘That brings us to the other major development—the
movement of hESC (human embryonic stem cell)-based thera-
peutics into the ﬁrst human clinical trials. Clearly this is just
the ﬁrst chapter in this development, and the remaining chap-
ters will be written in the coming years as Geron’s clinical
trial for spinal cord injury moves forward and others move
into clinical trials—probably for eye indications. Personally, I
think that clinical development will be the most important as-
pect of stem cell research over the next 10–15 years. How-
ever, it’s important for the public to recognize that we are
still probably 10–15 years away from the ﬁrst licensed
therapeutics.’’
‘‘It will also be important for the stem cell community to
continue to work toward addressing the key technical issues
that hinder successes in practical therapeutic applications
since clinical applications will be the most visible sign that
the battles over the ethical issues were worth ﬁghting. Uni-
form regulatory requirements for therapeutic stem cells will
take some time to achieve. This has been the case for other
biologics that have been in development much longer than
stem cells—monoclonal antibodies, for example. There are
groups, such as the International Conference on Harmonisa-
tion (ICH), that work to harmonize regulations, but very often
there is just general agreement at best with variations on exact
requirements from country to country. I think that regulatory
requirements for stem cells will continue to evolve as we
learn more about potential risks through animal studies and
human clinical trials. These ﬁndings will serve to shape the
regulatory landscape as the ﬁeld matures and the resulting
regulatory requirements may differ from one country to the
next.’’
‘‘Cell Banking Is a Key Aspect of Supporting
Research in This Field’’
‘‘I think that it’s important to recognize the importance of cell
banking, given that cell quality can have a huge impact on
research quality and subsequently clinical success. Banking
requires the development of an infrastructure for growing and
testing hESCs. Although some labs may like the idea of
receiving funding for cell banking, it is not typically a job
that labs are willing to make a long-term commitment to-
ward.’’ Dr. Hei notes that researchers in the United States are
still working on the impact of the new NIH research guide-
lines that went into effect in July 2009. ‘‘Although we now
have new approved hESC lines and NIH-funded hESC
research projects, many of these researchers have been forced
to work with new cell lines. To date, H1 is the only previous
NIH Registry hESC line that has been re-approved for use in
NIH-funded research. This represents a potential set-back for
NIH-funded research in the U.S. since switching a research
program to a new cell line is not typically a trivial matter.
Cell lines can behave very differently from one another.
Without a centralized source, such as the National Stem Cell
Bank, for distributing cells, there may be issues with the tim-
ing for cell receipt and potentially even the quality of the
cells that are distributed.’’
‘‘In my opinion, one of the biggest obstacles right now is
the lack of well characterized human ES cells that are avail-
able for NIH-funded research. This can be resolved either by
obtaining re-approval of the previous NIH-approved lines
under the Bush administration or by establishing a centralized
bank network that can help with banking, characterizing, and
distributing cell lines. Another major problem is that deposit-
ing cell lines is voluntary. From my perspective, it would be
more efﬁcient to work toward a centralized banking system
and encourage investigators to deposit their hESC lines.’’
‘‘It Is Important for the Public to Understand the
Practical Differences Between Human ES Cells and
Adult Stem Cells’’
Dr. Hei points out that although iPS cells are a promising
new technology that helps to avoid many of the difﬁcult ethi-
cal issues associated with hESCs, we are still early in the
learning process. ‘‘Human ES cells will continue to be impor-
tant for research and may continue to be the most suitable
Figure 1. Derek Hei, PhD. University of Wisconsin Stem Cell and
Regenerative Medicine Center.
388 Interview Seriescell type for allogeneic cell therapy applications. iPS cells
have a long way to go before there are clinical applications
but may offer long-term hope to address chronic diseases
where autologous therapeutics may be needed to address
immune rejection issues. It is important for the public to
understand the practical differences between human ES cells
and adult stem cells. Education is obviously critical. These
cell types are not necessarily interchangeable and each cell
type may be beneﬁcial for speciﬁc clinical applications.
Unfortunately, it will likely take many years of research and
human clinical studies to clearly understand the differences in
therapeutic potential between hESC, iPS, and adult stem cell
types.’’
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